Display options
Cite
Ma X, Li RS, Wang J, et al. The Therapeutic Efficacy and Safety of Compound Kushen Injection Combined with Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma: An Update Systematic Review and Meta-Analysis. Front Pharmacol. 2016;7:70doi: 10.3389/fphar.2016.00070.
Ma, X., Li, R. S., Wang, J., Huang, Y. Q., Li, P. Y., Wang, J., Su, H. B., Wang, R. L., Zhang, Y. M., Liu, H. H., Zhang, C. E., Ma, Z. J., Wang, J. B., Zhao, Y. L., & Xiao, X. H. (2016). The Therapeutic Efficacy and Safety of Compound Kushen Injection Combined with Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma: An Update Systematic Review and Meta-Analysis. Frontiers in pharmacology, 770. https://doi.org/10.3389/fphar.2016.00070
Ma, Xiao, et al. "The Therapeutic Efficacy and Safety of Compound Kushen Injection Combined with Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma: An Update Systematic Review and Meta-Analysis." Frontiers in pharmacology vol. 7 (2016): 70. doi: https://doi.org/10.3389/fphar.2016.00070
Ma X, Li RS, Wang J, Huang YQ, Li PY, Wang J, Su HB, Wang RL, Zhang YM, Liu HH, Zhang CE, Ma ZJ, Wang JB, Zhao YL, Xiao XH. The Therapeutic Efficacy and Safety of Compound Kushen Injection Combined with Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma: An Update Systematic Review and Meta-Analysis. Front Pharmacol. 2016 Mar 31;7:70. doi: 10.3389/fphar.2016.00070. eCollection 2016. PMID: 27065861; PMCID: PMC4814457.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2016 Mar 31;7:70. doi: 10.3389/fphar.2016.00070. eCollection 2016.

The Therapeutic Efficacy and Safety of Compound Kushen Injection Combined with Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma: An Update Systematic Review and Meta-Analysis.

Frontiers in pharmacology

Xiao Ma, Rui-Sheng Li, Jian Wang, Yin-Qiu Huang, Peng-Yan Li, Ji Wang, Hai-Bin Su, Rui-Lin Wang, Ya-Ming Zhang, Hong-Hong Liu, Cong-En Zhang, Zhi-Jie Ma, Jia-Bo Wang, Yan-Ling Zhao, Xiao-He Xiao

Affiliations

  1. Department of Pharmacy, 302 Military Hospital of People's Liberation ArmyBeijing, China; Pharmacy College, Chengdu University of Traditional Chinese MedicineChengdu, China.
  2. Research and Technology Service Center, 302 Military Hospital of People's Liberation Army Beijing, China.
  3. Pharmacy College, Chengdu University of Traditional Chinese Medicine Chengdu, China.
  4. China Military Institute of Chinese Medicine, 302 Military Hospital of People's Liberation Army Beijing, China.
  5. Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University Chengdu, China.
  6. Liver Failure Treatment and Research Center, 302 Military Hospital of People's Liberation Army Beijing, China.
  7. Department of Integrative Medical Center, 302 Military Hospital of People's Liberation Army Beijing, China.
  8. Pharmacy College, Chengdu University of Traditional Chinese MedicineChengdu, China; China Military Institute of Chinese Medicine, 302 Military Hospital of People's Liberation ArmyBeijing, China.
  9. Beijing Friendship Hospital, Capital Medical University Beijing, China.
  10. Department of Pharmacy, 302 Military Hospital of People's Liberation Army Beijing, China.

PMID: 27065861 PMCID: PMC4814457 DOI: 10.3389/fphar.2016.00070

Abstract

BACKGROUND: Compound Kushen Injection (CKI) is a Chinese patent medicine approved by the China Food and Drug Administration for the treatment of various types of solid tumors. CKI, combined with transarterial chemoembolization (TACE), is believed to increase the therapeutic efficacy of unresectable hepatocellular carcinoma (HCC). We report an updated and extended meta-analysis with detailed outcomes of both the efficacy and adverse events (AEs) of CKI combined with TACE therapy.

MATERIALS AND METHODS: Electronic databases, including PubMed, Embase, the Cochrane Library, the Chinese Biomedical Database (CBM), Wanfang, the VIP medicine information system (VMIS) and the China National Knowledge Infrastructure (CNKI), were examined for relevant articles before November 13, 2015. An odds ratio (OR) was used to estimate tumor response (TR), Karnofsky Performance Scale (KPS) improvement, Child-Pugh (CP) improvement, survival rate (SR) and AEs. A publication bias and a subgroup analysis were also assessed.

RESULTS: Eighteen studies, with a total of 1,338 HCC patients who met the criteria for the meta-analysis, were included. TR, KPS improvement and CP improvement were significantly enhanced for the combination therapy compared to TACE alone (OR = 1.84, 95% CI: [1.46, 2.33], P < 0.00001; OR = 2.37, 95% CI: [1.76, 3.18], P < 0.00001; OR = 1.81, 95% CI: [1.08, 3.03], P = 0.02, respectively). The combination therapy was associated with an improvement in 1-year and 2-year SRs but not an improved 3-year SR (OR = 2.40; 95% CI: [1.59, 3.62], P < 0.0001; OR = 2.49, 95% CI: [1.24, 5.00], P = 0.01; OR = 2.49, 95% CI: [0.94, 6.61], P = 0.07, respectively). A safety analysis indicated that AEs (including nausea/vomiting, fever, hepatalgia, increased transaminase, increased bilirubin and leukopenia) were reduced for the combination treatment compared to TACE alone.

CONCLUSION: The combination treatment of TACE and CKI was associated with improved TR, KPS and CP improvement and improved 1- and 2-year SRs in patients with unresectable HCC. The 3-year SR was not improved. The combination therapy resulted in a reduction in AEs. The findings of this study should be interpreted with caution because of the small sample size and study limitations.

Keywords: Compound Kushen Injection; meta-analysis; systematic review; transarterial chemoembolization; unresectable hepatocellular carcinoma

References

  1. Radiology. 2002 Jul;224(1):47-54 - PubMed
  2. Lancet. 2012 Mar 31;379(9822):1245-55 - PubMed
  3. Cardiovasc Intervent Radiol. 2010 Feb;33(1):41-52 - PubMed
  4. J Hepatol. 2012 Jun;56(6):1336-42 - PubMed
  5. Eur J Cancer. 2011 Sep;47(14):2117-27 - PubMed
  6. Planta Med. 2008 Feb;74(3):245-51 - PubMed
  7. Molecules. 2012 May 30;17(6):6481-90 - PubMed
  8. PLoS One. 2014 Mar 20;9(3):e91124 - PubMed
  9. Acta Pharmacol Sin. 2015 Jun;36(6):676-9 - PubMed
  10. BMJ. 2003 Sep 6;327(7414):557-60 - PubMed
  11. Phytother Res. 2012 Jun;26(6):932-7 - PubMed
  12. Am J Gastroenterol. 2008 Apr;103(4):914-21 - PubMed
  13. Lancet. 2012 Dec 15;380(9859):2095-128 - PubMed
  14. Curr Pharm Des. 2016;22(3):286-93 - PubMed
  15. Clin Cancer Res. 2014 Apr 15;20(8):2072-9 - PubMed
  16. Ann Intern Med. 2009 Aug 18;151(4):264-9, W64 - PubMed
  17. Hepatology. 2003 Feb;37(2):429-42 - PubMed
  18. J Hepatol. 2012 Dec;57(6):1258-67 - PubMed
  19. Gastroenterology. 2012 May;142(6):1264-1273.e1 - PubMed
  20. Lancet. 2002 May 18;359(9319):1734-9 - PubMed
  21. Aliment Pharmacol Ther. 2011 Jul;34(2):205-13 - PubMed
  22. Evid Based Complement Alternat Med. 2012;2012:373219 - PubMed
  23. Hepatology. 2002 May;35(5):1164-71 - PubMed
  24. Afr J Tradit Complement Altern Med. 2011 Dec 29;9(2):178-88 - PubMed
  25. J Clin Oncol. 2013 Oct 1;31(28):3501-8 - PubMed
  26. Evid Based Complement Alternat Med. 2013;2013:487919 - PubMed
  27. J Hepatol. 2012 Apr;56(4):908-43 - PubMed

Publication Types